Skip to main content

Daniela Samaniego Toro

Daniela Samaniego Toro

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, Malalties neurodegeneratives , Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Malalties neurodegeneratives , Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro, Daniela Samaniego Toro, Sara Belmonte Calderon
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI21/01603
Duration: 01/01/2022 - 30/06/2026

The Vall d’Hebron Iniciative for Parkinson associated to GBA (VHIP-GBA): from biospecimen collection to translational studies and therapies.

IP: Marta Martínez Vicente
Collaborators: José Antonio Arranz Amo, Jorge Hernández Vara, Eddie Pradas Gracia, Guillem Pintos Morell, Clara Carnicer Cáceres, Carles Lorenzo Bosquet, David Moreno Martinez, Jordi Riera Heredia, Marta Montpeyó Garcia-Moreno, Daniela Samaniego Toro, Laura Castillo Ribelles, Daniela Samaniego Toro
Funding agency: Instituto de Salud Carlos III
Funding: 245932.5
Reference: PI20/00728
Duration: 01/01/2021 - 30/06/2025

Related news

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Related professionals

Marta Fabregat Fernandez

Marta Fabregat Fernandez

Shock, Organ Dysfunction and Resuscitation
Read more
Marc Massa Gomez

Marc Massa Gomez

Research technician
Pneumology
Read more
Laura Barbera Ferrando

Laura Barbera Ferrando

Research technician
Read more
Dinara Samarkanova

Dinara Samarkanova

Main researcher
Transfusional Medicine
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.